# US 2024/0200115 A1 · Methods for increasing mannose content of recombinant proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0200115 A1
- Document ID: US20240200115A1
- Status: Published application
- Kind: A1
- Application number: 18/589,147
- Filed: 2024-02-27
- Published: 2024-06-20
- Earliest claimed: 2013-05-30
- Assignees: Amgen Inc.
- Applicants: Amgen Inc.
- Inventors: Chung-Jr HUANG, SR.; Xiaoming YANG
- Web page: https://patentgrep.com/patent/US20240200115A1

## CPC

- C12P 21/005: {Glycopeptides, glycoproteins}
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C12N 5/0018: {Culture media for cell or tissue culture (media for specific animal cell type C12N5/06)}
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C12N 2500/34: Sugars
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to methods of upregulating the high mannose glycoform content of a recombinant protein during a mammalian cell culture by manipulating the mannose to total hexose ratio in the cell culture media formulation.

## Claims

### Claim 1

A cell culture media containing mannose, wherein the mannose to total hexose ratio in the cell culture media is greater than 0 but less than 1.0.

### Claim 2 (depends on 1)

The cell culture media according to claim 1, wherein the cell culture media contains at least 3 g/L mannose.

### Claim 3 (depends on 1)

A method for upregulating the high mannose glycoform content of a recombinant protein during a mammalian cell culture process comprising:
establishing a mammalian cell culture in a bioreactor with a cell culture media that does not contain mannose; and
maintaining the cell culture with a cell culture media according to claim 1, wherein the high mannose glycoform content of a recombinant protein is increased compared to a culture where the cells are not subjected to a cell culture media containing a mannose to total hexose ratio of greater than 0 and less than 1.0.

### Claim 4

A method for upregulating the high mannose glycoform content of a recombinant protein during a mammalian cell culture process comprising:
establishing a mammalian cell culture in a bioreactor with a cell culture media that does not contain mannose:
growing the mammalian cells during a growth phase with a cell culture media that does not contain mannose:
initiating and maintaining a production phase in the cell culture by perfusion with a serum-free perfusion media containing mannose, wherein the mannose to total hexose ratio in the perfusion media is greater than 0 but less than 1.0.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the cell culture is maintained by perfusion.

### Claim 6 (depends on 4)

The method according to claim 4, wherein perfusion begins on or about day 3 to on or about day 9 of the cell culture.

### Claim 7 (depends on 4)

The method according to claim 4, wherein perfusion begins when the cells have reached a production phase.

### Claim 8 (depends on 4)

The method according to claim 4, wherein perfusion comprises continuous perfusion.

### Claim 9 (depends on 4)

The method according to claim 4, wherein the rate of perfusion is constant.

### Claim 10 (depends on 4)

The method according to claim 4, wherein perfusion is performed at a rate of less than or equal to 1.0 working volumes per day.

### Claim 11

The method according to 4, wherein the perfusion is accomplished by alternating tangential flow.

### Claim 12

The method according to 11, wherein the perfusion is accomplished by alternating tangential flow using an ultrafilter or a microfilter.

### Claim 13 (depends on 4)

The method according to claim 4, further comprising a temperature shift that occurs at the transition between the growth phase and the production phase.

### Claim 14 (depends on 4)

The method according to claim 4, further comprising a temperature shift that occurs during the production phase.

### Claim 15 (depends on 4)

The method according to claim 4, wherein the bioreactor has a capacity of at least 500 L.

### Claim 16 (depends on 4)

The method according to claim 4, wherein the mammalian cells are Chinese Hamster Ovary (CHO) cells.

### Claim 17 (depends on 4)

The method according, claim 4, wherein the recombinant protein is selected from the group consisting of a human antibody, a humanized antibody, a chimeric antibody, a recombinant fusion protein, or a cytokine.

### Claim 18 (depends on 4)

The method according to claim 4, further comprising a step of harvesting the recombinant protein produced by the cell culture.

### Claim 19 (depends on 4)

The method according to claim 4, wherein the recombinant protein produced by the cell culture is purified and formulated in a pharmaceutically acceptable formulation.

### Claim 20 (depends on 4)

The method of claim 4, wherein the high mannose glycoform content of a recombinant protein is increased compared to a culture where the cells are not subjected to a cell culture media containing a mannose to total hexose ratio of greater than 0 and less than 1.0.
